MetaCap

Oculis Holding AG (OCS)

NASDAQ: OCSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.06-0.38 (-5.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OCS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$393.35M
EPS (TTM)
-$1.69
52-week range
6.78 – 34.48
Day range
6.99 – 7.43
Volume / Avg
235.18K / 272.83K
Beta
—

52-week range

$6.78$34.48

OCS stock today

On Nov 20, OCS ended the session at $7.06, shedding $0.38 (5.11%), versus the S&P 500's 3.70% decline. Shares are 79.5% below their 52-week high of $34.48, set on May 11, 2026 and 4.1% above the 52-week low of $6.78, near the bottom of the past year's range. OCS is down 64.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.3%.

Oculis has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Oculis

Company profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Riad Sherif M.B.A., M.D.
Headquarters
Zug
Employees
60
Website
oculis.com

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$35.85+407.79%

  • Strong buy 3
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $19.36High $40.99

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.37 vs $-0.49
Surprise
+24.49%

OCS news

All OCS news

Oculis peers

Health Care sector
OCS peer companies
CompanyPrice% ChgMarket capCompare
AVTXAvalo Therapeutics Inc.6.76+0.15%$390.88Mvs OCS
IRDOpus Genetics Inc.3.99-2.21%$385.65Mvs OCS
PHATPhathom Pharmaceuticals Inc.4.66-8.27%$378.82Mvs OCS
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs OCS
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs OCS
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs OCS
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs OCS
ARVNArvinas Inc.6.46-4.15%$423.03Mvs OCS

Indexes, lists and sector

Oculis stock FAQ

What is Oculis's stock price today?

OCS last traded at $7.06 as of Nov 20, 4:00 PM EST, down 5.11% on the day. Prices are delayed at least 15 minutes.

Who is Oculis's CEO?

Dr. Riad Sherif M.B.A., M.D. is the chief executive officer of Oculis Holding AG, which has about 60 employees.

What is the OCS 52-week high?

The 52-week high for OCS is $34.48 and the 52-week low is $6.78. The stock is currently 79.5% below its high.

Compare OCS